TR201100151A2 - İbandronate formülasyonu. - Google Patents

İbandronate formülasyonu.

Info

Publication number
TR201100151A2
TR201100151A2 TR2011/00151A TR201100151A TR201100151A2 TR 201100151 A2 TR201100151 A2 TR 201100151A2 TR 2011/00151 A TR2011/00151 A TR 2011/00151A TR 201100151 A TR201100151 A TR 201100151A TR 201100151 A2 TR201100151 A2 TR 201100151A2
Authority
TR
Turkey
Prior art keywords
ibandronate
formulation
ibandronate formulation
prevention
pharmaceutically acceptable
Prior art date
Application number
TR2011/00151A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/00151A priority Critical patent/TR201100151A2/tr
Priority to TR2011/10526A priority patent/TR201110526A2/tr
Priority to TR2011/10524A priority patent/TR201110524A2/tr
Priority to TR2011/10525A priority patent/TR201110525A2/tr
Priority to PCT/TR2012/000008 priority patent/WO2012093977A1/en
Priority to EP12704937.7A priority patent/EP2661270A1/en
Priority to PCT/TR2012/000010 priority patent/WO2012093979A1/en
Priority to PCT/TR2012/000007 priority patent/WO2012093976A1/en
Priority to PCT/TR2012/000006 priority patent/WO2012093975A1/en
Publication of TR201100151A2 publication Critical patent/TR201100151A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş; kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere geliştirilmiş ibandronat ve/veya farmasötik açıdan uygun herhangi bir türevini içeren suda çözünür dozaj formlarını açıklamaktadır.
TR2011/00151A 2011-01-06 2011-01-06 İbandronate formülasyonu. TR201100151A2 (tr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.
TR2011/10526A TR201110526A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik formülasyonlar.
TR2011/10524A TR201110524A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.
TR2011/10525A TR201110525A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.
PCT/TR2012/000008 WO2012093977A1 (en) 2011-01-06 2012-01-03 Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
EP12704937.7A EP2661270A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
PCT/TR2012/000010 WO2012093979A1 (en) 2011-01-06 2012-01-06 Water-soluble dosage forms comprising ibandronate
PCT/TR2012/000007 WO2012093976A1 (en) 2011-01-06 2012-01-06 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
PCT/TR2012/000006 WO2012093975A1 (en) 2011-01-06 2012-01-06 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.

Publications (1)

Publication Number Publication Date
TR201100151A2 true TR201100151A2 (tr) 2012-07-23

Family

ID=46457629

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.

Country Status (3)

Country Link
EP (1) EP2661270A1 (tr)
TR (1) TR201100151A2 (tr)
WO (1) WO2012093979A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104922060B (zh) * 2015-05-23 2017-10-20 河北仁合益康药业有限公司 一种伊班膦酸钠注射液组合物
CN107670103A (zh) * 2017-09-15 2018-02-09 天津大学 聚乙烯吡络烷酮改性的骨水泥及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
US20060034921A1 (en) * 2004-01-05 2006-02-16 Katdare Ashok V Effervescent bisphosphonate formulation
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
WO2012093979A1 (en) 2012-07-12
EP2661270A1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
IN2014DN10670A (tr)
PH12017501306A1 (en) Inhibitors of histone demethylases
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
EA202092456A2 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
TW201129382A (en) Antibody formulation and therapeutic regimens
IN2014MN00948A (tr)
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201691695A1 (ru) Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
PH12014500386A1 (en) Combination treatment for hepatitis c
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
EA201270728A1 (ru) Пуриновые соединения
TR201004464A2 (tr) Kemik erimesi için formülasyon.
EA201171414A1 (ru) Ингибиторы белков семейства iap
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.